Core Viewpoint - Harrow has announced a private offering of $50 million in senior unsecured notes due 2030, aimed at supporting general corporate purposes and growth initiatives [1][3]. Group 1: Offering Details - The offering consists of $50 million aggregate principal amount of 8.625% senior unsecured notes due September 15, 2030 [1][2]. - The notes will be issued as additional notes under the same indenture as the existing $250 million 2030 notes issued on September 12, 2025, and will be treated as a single series [2]. - The offering price for the new notes is set at 100.25% of the principal amount plus accrued interest from March 15, 2026 [2]. Group 2: Use of Proceeds - The net proceeds from the issuance will be utilized for general corporate purposes, including growth initiatives, product development, and strategic business opportunities [3]. Group 3: Company Overview - Harrow is a leading provider of ophthalmic disease management solutions in North America, focusing on a range of eye conditions [7]. - The company is committed to delivering safe, effective, and affordable medications to enhance patient compliance and improve clinical outcomes [7].

Core Viewpoint - Harrow intends to offer an additional $50 million in senior unsecured notes due 2030 to support growth initiatives and product development [1][2] Group 1: Offering Details - The additional $50 million in 8.625% senior unsecured notes will be guaranteed by the company's existing and future wholly-owned domestic restricted subsidiaries [1] - These notes will be issued under the same indenture as the previously issued $250 million of 2030 Notes, treated as a single series with identical terms except for issuance date and price [1] Group 2: Use of Proceeds - The net proceeds from the issuance will be utilized for general corporate purposes, including growth acceleration initiatives, new product launches, and strategic business development opportunities [2] Group 3: Regulatory Information - The 2030 Notes and related guarantees are not registered under the Securities Act and will be offered only to qualified institutional buyers or non-U.S. persons [3][4]

Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products for various eye conditions including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [2] - The company was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes [2] Upcoming Events - Management will present at Leerink Partner's 2026 Global Healthcare Conference on March 10, 2026, at 8:40 AM ET in Miami, Florida [1] - The presentation will be webcast live and available for replay on the company's website for approximately 90 days following the event [1]

Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, will report its financial results for Q4 and the full year of 2025 on March 2, 2026, and will host a conference call on March 3, 2026, to discuss these results and provide a business update [1]. Group 1: Financial Reporting - The financial results for the fourth quarter and year ended December 31, 2025, will be announced after market close on March 2, 2026 [1]. - A Letter to Stockholders for the fourth quarter will be posted on the "Investors" section of Harrow's website [1]. Group 2: Conference Call Details - A conference call and live webcast will take place at 8:00 a.m. Eastern Time on March 3, 2026, to discuss the financial results and provide a business update [1]. - Participants can access the live webcast on the "Investors" page of Harrow's website, and a replay will be available for one year [2]. - Telephone participants must register in advance to receive a unique dial-in number and PIN for accessing the call [2]. Group 3: Company Overview - Harrow, Inc. is a prominent provider of ophthalmic disease management solutions, offering a comprehensive portfolio of products for various eye conditions, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [3]. - The company is committed to delivering safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [3].

Core Insights - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on a comprehensive portfolio of products for various eye conditions [2] Upcoming Events - Harrow management will participate in two investor conferences in December 2025: - BTIG 5th Annual Ophthalmology Day (Virtual) on December 1, 2025, at 8:30 AM EST [1] - Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025, at 3:00 PM EST, which will be webcast live [1] Company Overview - Harrow offers solutions for conditions affecting both the front and back of the eye, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [2] - The company is committed to providing safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [2]

Core Insights - Harrow has announced leadership changes at its subsidiary ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality [2][5] Leadership Appointments - Frank Mullery brings over 20 years of experience in healthcare and pharmaceuticals, having previously served as President of Sintetica US and held senior roles at STI Pharma and Mylan, where he led significant revenue growth and product launches [3] - Bridseida Cruz has over 25 years of experience in quality and operations, known for her work in FDA remediation and operational efficiencies, including launching a new FDA-registered compounding facility that improved throughput by 20% [4] Company Vision - Harrow's CEO Mark L. Baum expressed confidence in the new leadership, emphasizing the importance of fulfilling unmet needs in U.S. eyecare and positioning ImprimisRx as a leader in ophthalmic compounding [5] Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on safe, effective, and affordable medications for various eye conditions [6]